Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis

Study of HLA Polymorphisms in French West-Indian Patients With Rheumatoid Arthritis : A Case Control Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01111357

Acronym

HLAPRPA

Enrollment

200

Registered

2010-04-27

Start date

2010-02-28

Completion date

2010-08-31

Last updated

2010-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Rheumatoid Arthritis, Rheumatoid Arthritis according to ACR criteria of diagnosis

Brief summary

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.

Interventions

BIOLOGICALCollect of 10 ml of peripheric blood for DNA extraction

After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of Rheumatoid Arthritis according to ACR criteria * Come from French West Indies (At least 3 grandparents are African-Caribbean) * Sign written informed consent

Exclusion criteria

* Minor * Patient with no Rheumatoid Arthritis according to ACR criteria * Patient does not agree for a genetic study For the control Inclusion Criteria: * Blood donor * Sign written informed consent * Patient with no Rheumatoid Arthritis according to ACR criteria * Come from French West Indies (At least 3 grandparents are African-Caribbean)

Design outcomes

Primary

Measure	Time frame
Difference of distribution of HLA alleles in patients and in healthy controls	1 day

Secondary

Measure	Time frame
The association between the different HLA alleles among French West-Indian RA patients and the autoantibodies production.	1 day
The association between the different HLA alleles among French West-Indian RA patients and the radiological damage.	1 day
The association between the different HLA alleles among French West-Indian RA patients and the response to therapy	1 day

Countries

Martinique

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026